Joseph Pantginis


Capricor Therapeutics Inc (CAPR) Investors Throw Bullish Parade After H.C. Wainwright Boosts Price Target

Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.

Rodman and Renshaw Sings the Praises of Capricor Therapeutics, Inc. (CAPR); Here’s Why

On Tuesday, Capricor Therapeutics, Inc. (NASDAQ:CAPR) was granted FDA Rare Pediatric Disease Designation for CAP-1002, the company’s treatment for Duchenne muscular dystrophy (DMD) and …

Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial  at the American Society …

Sophiris Bio Inc (SPHS): Phase 2b Trial One Step a Way to Take Off

Drug maker Sophiris Bio Inc (NASDAQ:SPHS) released its earnings report for the first quarter of 2017 and is one step closer to beginning Phase …

Sophiris Bio Inc (SPHS): Prostate Cancer Drug Continues To Impress

Following Sophiris Bio Inc’s (NASDAQ:SPHS) fourth-quarter and 2016 financial results released yesterday coupled with last week’s update on its prostate cancer program, Rodman …

Rodman & Renshaw Initiates Buy on Sophiris Bio Inc (SPHS), Sees 113% Upside for the Stock

Sophiris Bio Inc (NASDAQ:SPHS) shares are rising almost 17% on back of Rodman & Renshaw analyst Joseph Pantginis initiating coverage on SPHS with …